ABSTRACT
INTRODUCTION
The study and application of somatic cell nuclear transfer (NT) technology in mammals offers many benefits for research, biomedicine, and agriculture [1, 2] . In addition to providing a route for genetic modification in livestock and production of biopharmaceuticals, NT will extend the range of species in which desired genetic alterations of the ge- nome are possible and, thereby, also may provide better models for the treatment of human diseases [3] [4] [5] . Other potential applications include the conservation and preservation of endangered breeds [6] and species [7] .
An increasing variety of mammalian species, including bovine [8] , have been cloned using somatic cell NT [9] [10] [11] [12] . However, the efficiency of this technique is very low, with less than 6% of reconstructed NT embryos typically developing into live offspring [13] . Although major losses occur during the first 14 days after transfer of cloned blastocysts, the primary cause of subsequent fetal loss appears to be associated with functional placental deficiencies [14] . Placental abnormalities in cattle and sheep following transfer of cloned embryos have been recently documented and include increased placental weights and low placentome number [15, 16] , enlarged umbilical vessels [8] , and edematous membranes as well as increased allantoic fluid volume [8] . To our knowledge, the causes of these abnormalities remain unknown.
Placental growth and differentiation are regulated by mechanisms that involve numerous endocrine and paracrine signals. Cytokines, such as members of the transforming growth factor (TGF) ␤ family and members of the insulinlike growth factor (IGF) family, are actively synthesized by the ruminant placenta [17] . Systemic IGF-I in the fetus is an important determinant of the partitioning of nutrients between the fetus and placenta to favor fetal growth [18] . In the fetus, skeletal muscle and liver are major sites of IGF-I synthesis and potential sources of circulating IGF-I [19] , although the placenta is actively involved in the regulation of IGF-I plasma concentrations [18] . The actions of the IGF family are regulated through their association with high-affinity binding proteins (IGFBPs) that determine their bioavailability. The IGFBPs also appear to mediate IGFindependent actions, such as inhibition or enhancement of growth and induction of apoptosis. The actions of IGFs are also regulated by IGFBP proteases, which affect the relative affinities of IGFBPs, IGFs, and IGF-I receptor for each other [20] . To date, six different high-affinity binding proteins (IGFBP-1 through -6) have been identified that specifically bind IGF-I and -II. Furthermore, IGFBP-1, -3, and -4 bind IGF-I and -II with similar affinities, whereas IGFBP-2, -5, and -6 preferentially bind IGF-II [21] . In bovine serum, the most abundant IGF carrier protein is IGFBP-3, which binds more than 95% of the IGF-I and -II in the circulation [20] . In the uterus, IGFBP-1 is found solely in the luminal epithelium, where it is reported to play an important role in regulating the transport of IGFs between the endometrium and the uterine lumen [22, 23] . In addition, IGFBP-1 is the predominant binding protein in amniotic fluid and a major carrier protein in fetal serum, and its concentrations are increased in the maternal circulation during pregnancy [24] . In humans, IGFBP-1 is implicated to play a role in the abnormalities of placental development observed in preeclampsia [25] . The IGFBP-2 is primarily expressed by the maternal caruncular tissues, and its interaction with IGF-II may influence trophoblast function [22] . Circulating levels of IGFBP-2 are significantly increased in large-offspring fetuses following embryo culture. Liver expression is also markedly increased [26] . In the sheep, IGFBP-3 mRNA is expressed in the caruncular stroma, uterine luminal epithelium, and myometrium but is most abundant in the maternal blood vessel walls, where it may have an important role in angiogenesis [27, 28] .
To our knowledge, no study has documented the spatial and temporal distributions of IGFs and IGFBPs in the cloned bovine placentome during early pregnancy. The aim of the present study was to determine if endocrine and paracrine factors involved in the regulation of normal placental growth, development, and function are dysregulated in cattle that are pregnant with embryos generated by NT.
MATERIALS AND METHODS
Investigations were conducted in accordance with the regulations of the New Zealand Animal Welfare Act of 1999. The generation of embryos for transfer to recipients or artificial insemination (AI) of the heifers was carried out in two separate experiments, conducted approximately 2 mo apart, with equal numbers of animals used for each experiment. All dams and recipients were 2-yr-old heifers of predominantly dairy or dairy-cross breeds.
Oocytes for in vitro-produced (IVP) embryos or cytoplasts for NT were obtained from the same pool of ovaries collected from Friesian cows at the slaughterhouse. In vitro maturation of oocytes was carried out as previously described [8] .
NT Embryos
The methods used to generate the cloned (NT) embryos have been described previously [8] . An ovarian follicular cell line (EFC) derived from a 4-yr-old Friesian dairy cow and demonstrated to be totipotent following NT, as described by Wells et al. [8] , was used in the present study. Donor cells used for NT had been previously cryopreserved and were obtained after at least nine cell passages in culture. Cells were cultured in a 1:1 mixture of Dulbecco modified Eagle medium and F12 (Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal calf serum (FCS; Invitrogen) and sodium pyruvate to a final concentration of 1 mM. To induce the cells into a quiescent state, the FCS concentration in the medium was reduced to 0.5%, and the cells were cultured for a further 9-11 days before being used for NT. After injection of the donor cells into the perivitelline space between the zona pellucida and the cytoplast, electrically mediated cell fusion was performed at 22-24 h after the start of maturation. Two direct current electrical pulses of 2.25 kV/cm for 10 sec each were delivered to individual, manually aligned donor cell-cytoplast couplets in a fusion chamber comprising two parallel electrodes spaced 500 m apart and in 0.3 M mannitol-based buffer [8] . Successfully fused reconstructed embryos were activated 27-28 h after the start of maturation using a combination of 5 M ionomycin (Sigma, Sydney, Australia) for 4 min followed by incubation in 2 mM 6-dimethylaminopurine (Sigma) for a further 4 h. After activation, in vitro culture was carried out essentially as described previously [29] in a biphasic AgResearch Synthetic Oviduct Fluid medium (AgR SOF; AgResearch, Hamilton, New Zealand). This medium was replaced on Day 4 of culture with fresh AgR SOF containing 10 M 2,4-dinitrophenol as an uncoupler of oxidative phosphorylation [30] . The fatty acid-free bovine albumin (8 mg/ml) in the AgR SOF was ABIVP (ICP Bio, Auckland, New Zealand). On Day 7 postfusion, 49 NT embryos judged to be of suitable quality by a subjective grading system were transferred into recipient heifers.
IVP Embryos
In vitro-matured oocytes were fertilized with frozen-thawed spermatozoa in 50-l drops under oil for 24 h as described previously [30] . The frozen semen used was obtained from the same Friesian bull that sired the dairy cow from which the EFC cells were isolated. After fertilization, the zygotes were cultured as described for NT embryos. On Day 7 after fertilization, embryos of suitable quality were transferred to recipients.
Artificial Insemination
Twenty-one Friesian heifers were synchronized for estrus using intravaginal CIDR progesterone-release breeding devices (Pharmacia Ltd., Auckland, New Zealand) inserted for 12 days. On Day 8, all heifers were injected with 1 ml of estrumate (Schering-Plough, Union, NJ), and the CIDR devices were withdrawn after a further 4 days. The mean onset of estrus was approximately 48 h later. Approximately 12 h after the onset of estrus, frozen-thawed semen obtained from the same bull described above was used for AI.
Recipients for IVP or NT Embryos
Friesian or dairy crossbred heifers (n ϭ 70) were synchronized by a single 12-day CIDR breeding device concurrent with those heifers used for AI as described above. On the seventh day after observed estrus, 19 single-IVP and 49 single-NT embryos were transferred nonsurgically into the uterine lumen ipsilateral to the corpus luteum of each heifer.
Pregnancy Monitoring
From Day 40 of gestation until slaughter, pregnancy establishment and rates in all heifers were determined by monthly transrectal ultrasonographic examination using a Piemed 200 scanner with a linear 3.5-to 5-MHz rectal probe (Philip-sweg, Maastricht, The Netherlands). Fetal heartbeats were recorded from Day 60 onward. On Day 40, only the presence of a gestation sac was recorded.
Tissue and Fluid Collection
Maternal blood samples were obtained from the tail vein during ultrasound scanning. A sample of pregnant animals from each group was slaughtered on Days 50, 100, and 150 of gestation, and the reproductive tracts were collected and transported to the laboratory within 1 h. Caruncles were removed and trimmed of their associated membranes. Fetal fluids (amniotic and allantoic) were collected at all three gestation intervals, and fetal blood was collected at Day 150. Fetal fluids and serum were stored at Ϫ20ЊC pending analysis. Both fetal and maternal cotyledon tissues and tissue from intact placentomes were snap-frozen in liquid nitrogen or fixed in formalin-buffered PBS.
Immunohistochemistry
Two placentomes from each heifer were removed and placed in formalin-buffered PBS for sectioning, staining, and subsequent histological and immunohistochemical analysis. Antibodies to IGF-I and -II as well as IGFBP-1, -2, and -3 were raised in rabbits against recombinant human (rh) IGF-I (Genentech, South San Francisco, CA), rhIGF-II (Eli Lily and Company, Indianapolis, IN), ovine (o) IGFBP-1 (sequence amino acids 105-121; Gropep, Thebarton, Australia), and oIGFBP-2 and -3 purified from sheep serum (Gropep) [31] [32] [33] . Antibodies were localized in placentomes by immunoperoxidase staining employing the avidin-biotin complex (ABC) for immunostaining of paraffin-embedded sections (Vector Laboratories, Burlingame, CA). Tissues were embedded in paraffin wax, sectioned (thickness, 5 m), and mounted on chrome alum-coated slides. Tissues were deparaffinized in xylene and rehydrated through graded alcohols. Endogenous peroxidase activity was depleted by incubation with 0.3% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min at room temperature. Tissues were preincubated for 30 min with normal goat serum diluted 1:200 to block nonspecific binding, then incubated with the appropriate dilution of antiserum-IGF-I (1:1500), IGF-II (1:200), IGFBP-1 (1: 800), IGFBP-2 (1:800), and IGFBP-3 (1:600)-for 24 h at 4ЊC. After primary antibody incubations, tissues were washed in PBS and incubated with biotinylated goat anti-rabbit immunoglobulin G for 2 h at room temperature followed by streptavidin-peroxidase conjugate for 20 min each at room temperature. After a further PBS wash, the tissues were incubated in diaminobenzidine until a positive reaction was observed (20-90 sec). Normal rabbit serum and antiserum preabsorbed with excess antigen were used as negative controls. Neutralization of immunoreactivity was defined as a marked reduction in staining intensity in the presence of antigen. Slides were photographed at 400ϫ magnification. A double-blind procedure was used to assess immunohistochemical scores based on staining 
Cell Count
Paraffin-embedded sections were stained with hematoxylin and eosin and with methyl green nuclear counterstain to assess fetal and maternal cell numbers. Binucleate cell numbers were determined by immunostaining with bovine placental lactogen (bPL; a marker gene of binucleate cells) [34] . Antibodies to bPL (a gift from J.C. Byatt, Monsanto Animal Agriculture Group, St Louis, MO), were raised in rabbit against purified native bPL [35] and used at a final dilution of 1:10 000. The ABC method of immunostaining was employed as described above. Cell counting was performed using a double-blind procedure, and random fields were assigned. A standard grid was used over high-power-field microscopic views (100ϫ magnification). Six random fields were examined within a 1-ϫ 1-cm ocular grid per section. All fetal trophectodermal mononucleate and binucleate and maternal uterine epithelial cells were counted at Days 50, 100, and 150 of gestation. One representative slide from each placentome (two placentomes per cow) was assessed.
Radioimmunoassays
Levels of IGF-I and -II and IGFBP-1 in fetal and maternal serum and fetal fluids (amniotic and allantoic) were measured using specific RIAs [33] . The same primary antibodies used for immunohistochemistry were used for the RIAs (see above). Cold recoveries and parallelism were performed on all bovine fluids. The limits of detection for serum IGF-I and IGFBP-1 and for amniotic and allantoic fluid IGFBP-1 were 1.0, 1.0, 0.2, and 0.3 ng/ml, respectively. Intra-and interassay coefficients of variation were less than 10%. Assays for IGFBP-2 and-3 were not available.
Statistical Analysis
Statistical analyses were carried out using a Sigma Stat (Jandel Scientific, San Rafael, CA) package. Differences between groups were determined by parametric (one-way ANOVA with post-hoc Tukey) tests. Data are shown as the mean Ϯ SEM. Statistical significance was accepted at P Ͻ 0.05.
RESULTS

Histological Examination
The cellular morphology of AI/IVP versus NT placentomes was similar at Days 50, 100, and 150 of gestation. The bovine cotyledon consisted of numerous slender chorionic villi accommodated within the crypts of the uterine mucosa. Each villus was composed of a core of vascular mesoderm covered by a layer of cuboidal trophoblast cells, many of which were binucleated. The maternal epithelium was composed of cuboidal cells interspersed with low columnar cells having centrally located nuclei. The basic descriptions of the cytology of the maternal and fetal compartments are in general agreement with those described by Björkman [36] .
Despite similar cytological appearance, a significant increase was observed in fetal, maternal, and binucleate cell numbers in NT placentomes compared with AI/IVP controls at all gestational ages examined ( Table 1) . Furthermore, binucleate cell counts at Days 50, 100, and 150 of gestation were almost threefold higher in NT placentomes than in AI/IVP placentomes. Immunostaining with bPL allowed easy visualization of binucleated cells (which stained dark brown in all placentomes examined at Days 50, 100, and 150) and allowed comparison of binucleate cell numbers between AI, IVP, and NT placentomes, as illustrated in Figure 1 . Cell numbers remained relatively constant throughout gestation, although maternal cell numbers were consistently higher than fetal cell numbers in all groups from Days 50 through 150 of gestation.
Immunolocalization of IGFBPs at Days 50, 100, and 150 of Gestation
The presence of IGFBP-1 was found in the deep uterine glands of the maternal placentome. Fetal villi did not stain for IGFBP-1. Immunoperoxidase staining was of moderate intensity in all AI, IVP, and NT placentomes. Negative controls showed no staining. No differences were observed in the localization of IGFBP-1 or staining intensity in AI, IVP, and NT placentomes with advancing gestation. A representative photograph (from n ϭ 10 placentae) of IGFBP-1 staining at Day 50 of gestation is shown in Figure 2A . Localization and immunohistochemical scores are shown in Table 2 .
Expression of IGFBP-2 was localized to the deep stromal tissue of the maternal placentome in all groups examined (Fig. 2, B-F) . Intensity of stromal staining was moderate in the AI placentomes at Days 50 ( Fig. 2B) and 100 (Fig. 2D ) of gestation, with no visible staining at Day 150 of gestation. Placentomes from IVP pregnancies showed similar staining patterns (not shown). In contrast, intense staining of the stroma was observed in the NT placentome (Fig. 2, C and E) at Days 50 and 100 of gestation. The deep uterine glands and apical and medial regions (Fig.  2E ) of the stromal tissue were immunonegative for IGFBP-2. Maternal crypt and fetal villous tissue was also immunonegative in AI, IVP, and NT placentomes. The AI, IVP and NT placentomes were immunonegative for IGFBP-2 at Day 150 of gestation. No staining was detected in negative controls (Fig. 2F) .
Localization of IGFBP-3 was found in both fetal trophectodermal and maternal uterine tissue in NT placentomes, with strong, generalized staining for the three gestational periods examined (Fig. 2, H, J, and L) . Little or no staining was observed for IGFBP-3 in AI and IVP (not shown) placentomes at all stages of gestation (Fig. 2, G, I , and K). No staining was observed in the negative control (Fig. 2M) .
Localization of IGF-I and -II on Days 50, 100, and 150 of Gestation
Generalized, moderate to intense staining for IGF-I was observed in both fetal villous and maternal stromal and epithelial tissue in all placentomes at all stages of gestation examined, with no apparent differences between the three groups (data not shown). The IGF-II immunoreactivity was similar to the observations for IGF-I in terms of both localization and degree of staining intensity. Negative controls showed no staining.
RIA Data
Concentrations of IGF-I in fetal serum on Day 150 of gestation were significantly higher (P ϭ 0.001) in NT pregnancies (30.3 Ϯ 2.3 ng/ml; n ϭ 8) compared with AI (19.1 Ϯ 5.5 ng/ml; n ϭ 5) or IVP (24.2 Ϯ 2.5 ng/ml; n ϭ 3) pregnancies (Table 3) 
DISCUSSION
Evidence from morphological studies of cloned pregnancies suggests that abnormal placental growth, development, and function contribute to poor fetal viability in these pregnancies. Perhaps the most striking observation in many NT pregnancies is the presence of large placentomes [13, 37, 38] . Histological examination of NT placentas suggests that hyperplasia of the placentome may be a compensatory mechanism secondary to reduced placentome number or may arise from aberrations in trophoblastic cell differentiation and function [15, 39] .
Histological examination of NT versus AI/IVP placentomes indicated that fetal and maternal cell numbers were significantly increased in NT versus AI/IVP placentomes, suggesting that a combination of both cotyledonary and caruncular abnormalities contributes to the aberrant development of the placenta. Furthermore, binucleate cell numbers were markedly increased in NT placentas to almost threefold that of AI and IVP placentas. This observation could be explained by increased binucleate cell formation and/or decreased rate of binucleate cell migration across the fetomaternal interface of the NT placenta. These findings augment earlier reports by Farin et al. [40] , who observed increased volume densities of binucleate cells in bovine placentas produced in vitro (but not in the IVP embryos of the present study). Binucleate cells play a central role in formation of the placental syncytium and secretions at the fetomaternal interface that are crucial in maintaining pregnancy [41] . As such, the observed increase in cell numbers likely has significant implications for fetomaternal communication and may contribute to the placental overgrowth observed in the NT placentome; however, the mechanisms by which this occurs remain largely unknown.
Various components of the IGF system have been localized to the bovine uterus and placenta, where they show spatial and temporal patterns of expression [42, 43] . In the placenta, the IGFs promote cellular mitosis and differentiation, migration and aggregation, as well as inhibition of apoptosis [23] . Variations in the pattern of expression of either IGF-I or -II have a range of effects on placental growth. Small placentas are found in IGF-II knockout mice, whereas mice that overexpress IGF-II exhibit placental edema [44] . Furthermore, disruption of the IGF-II receptor, with an associated reduction in IGF-II clearance, leads to placental hypertrophy [45, 46] . Many of these features have been reported in cloned animals [13, 15, 16] . In the present study, we have investigated the hypothesis that differences in the expression of IGFs and IGFBPs in NT pregnancies may be fundamental to the placental abnormalities that are seen in cloned cattle. To our knowledge, this is the first study to document differences in IGFs/IGFBPs in bovine NT pregnancies early during gestation.
The results of the present study demonstrate that serum IGF-I levels were significantly increased in NT fetuses at Day 150 of gestation compared to IVP and AI controls. In contrast, Chavatte-Palmer et al. [16] found no difference in IGF-I concentrations in cloned calves compared to controls. However, IGF-I concentrations are dramatically reduced after birth [18] . A dominant influence on fetal IGF-I levels, at least during the later stage of gestation, is nutrient status, particularly glucose availability to the fetus [18] . Defects in energy metabolism, such as hyperinsulinemia and hypoglycemia, have been reported in a number of calves following NT [47] . Increased IGF-I levels in fetal serum therefore may reflect altered energy metabolism in NT fetuses, perhaps because of adaptations made by the conceptus to abnormal placental function. The liver is the major source of circulating IGF-I, and increased liver weights have been reported in cloned sheep [38] and cattle fetuses (unpublished data). Alterations in hepatic synthesis or clearance of IGF-I, perhaps induced by placental deficiencies, may give rise to the increased liver weights often associated with NT fetuses. Alternatively, elevated fetal IGF-I levels might cause disturbances in placental growth and development. Fetal IGF-I concentrations have been significantly and positively correlated with fetal weight and placental mass [48] . Recently, Gadd et al. [48] showed how such changes in placental mass are correlated with alterations in the pattern of expression of the IGF system within the uteroplacental unit of sheep.
In the present study, maternal serum concentrations of IGF-I and IGFBP-1 were similar between groups, and no differences in amniotic fluid IGFBP-1 levels were observed. To the contrary, Bertolini and Anderson [37] reported increased maternal plasma concentrations of IGF-I and -II in IVP pregnancies throughout gestation, although no data were presented. Furthermore, those authors described alterations in the IGFBPs within amniotic and allantoic fluids of IVP pregnancies before Day 90 of gestation. Similarly, we observed significantly increased allantoic fluid IGFBP-1 concentrations at Day 50 of gestation in NT pregnancies. These findings are coincident with an increase in allantoic fluid volumes in Day 50 NT pregnancies (unpublished data). Allantoic fluid is normally absorbed by 64.4 Ϯ 6.4 (6) 98.4 Ϯ 5.6 (8) 75.1 Ϯ 3.0 (4) 89.1 Ϯ 7.1 (7) 84.3 Ϯ 3.5 (6) 78.2 Ϯ 8.3 (5) 84.1 Ϯ 3.6 (4) 70.5 Ϯ 9.8 (5) 84.9 Ϯ 6.3 (5) 92.0 Ϯ 9.6 (4) 124.4 Ϯ 7.5 (4) 89.9 Ϯ 16.3 (3) 80.7 Ϯ 9.1 (4) 97.1 Ϯ 13.3 (4) 62.8 Ϯ 4.8 (14) 100.2 Ϯ 5.9 (10) 95.8 Ϯ 9.7 (9) 82.8 Ϯ 11.1 (3) 103.2 Ϯ 9.4 (5) 94.4 Ϯ 7.3 (8) 96.3 Ϯ 11.6 (6) IGFBP-1  40  48  60  69  95  117  145 4.0 Ϯ 0.5 (6) 4.5 Ϯ 0.5 (8) 3.8 Ϯ 1.0 (4) 3.8 Ϯ 1.1 (7) 2.1 Ϯ 0.3 (6) 4.3 Ϯ 1.1 (5) 1.2 Ϯ 0.3 (4) 6.1 Ϯ 2.2 (5) 5.3 Ϯ 1.49 (5) 4.9 Ϯ 1.8 (4) 4.9 Ϯ 1.8 (4) 1.9 Ϯ 0.3 (3) 6.4 Ϯ 2.7 (4) 1.3 Ϯ 0.1 (4) 3.4 Ϯ 1.7 (14) 5.2 Ϯ 0.8 (10) 3.2 Ϯ 0.4 (9) 3.2 Ϯ 0.4 (3) 1.8 Ϯ 0.3 (5) 5.2 Ϯ 2.2 (8) 1.6 Ϯ 0.3 (6) Amniotic fluid (ng/ml) IGFBP-1 50 100 150
1.20 Ϯ 0.30 (5) 1.20 Ϯ 0.20 (3) 0.40 Ϯ 0.10 (4) 1.60 Ϯ 0.60 (3) 0.90 Ϯ 0.40 (3) 0.70 Ϯ 0.20 (3) 0.90 Ϯ 0.10 (9) 0.90 Ϯ 0.10 (4) 0.70 Ϯ 0.10 (7) Allantoic fluid (ng/ml) IGFBP-1 50 100 150 0.90 Ϯ 0.10 (4) 0.50 Ϯ 0.20 (4) 1.00 Ϯ 0.01 (4) 0.80 Ϯ 0.10 (3) 0.70 Ϯ 0.20 (3) 1.00 Ϯ 0.01 (3) 1.40 Ϯ 0.10 (9)b 0.90 Ϯ 0.80 (3) 0.90 Ϯ 0.01 (9) a Values are mean Ϯ SEM. b P Յ 0.001, NT versus AI/IVP.
the placenta. However, in the case of NT pregnancies, fluid is retained, perhaps because of the inability of the lower number of caruncles to maintain the balance [49] . An alteration in the function of the allantoic membrane, perhaps because of altered hormonal status of the cow, also may contribute to hydrallantois [38, 50] . No differences of amniotic or allantoic IGFBP-1 concentrations were observed in NT versus AI/IVP at Day 100 or 150 of gestation. This may reflect a dilution of IGFBP-1 with increased fetal fluid volumes in NT pregnancies at later gestational stages. In addition to the systemic actions considered above, immunoperoxidase staining of IGFBPs in NT pregnancies showed significant differences compared to AI/IVP placentas, although staining of IGF-I and -II did not differ. The spatial and temporal patterns of IGF-I and -II expression reported here are in agreement with studies described elsewhere [42, 43] . Whereas IGFBP-1 expression in AI, IVP, and NT placentomes was similar at Days 50, 100, and 150 of gestation, expression of both IGFBP-2 and -3 was significantly increased in placental tissues from NT pregnancies. Increased expression of IGFBP-2 and -3 in NT placentas may indicate either increased production or upregulation by other growth effectors. Signals for increased production of the binding proteins may emanate from the placenta in response to either altered availability of IGF-I and -II or upregulation by other cytokines and cell-cycle regulators, such as TGF␤, retinoic acid, or p53 [51, 52] . However, we found no difference in immunoperoxidase staining of IGF-I and -II between NT and AI placentas. Increased retention of IGFs or reduced proteolysis and induction of IGF-independent action may reduce expression of IGFs, limiting their bioavailability. Martin and Baxter [53] showed that in T47D breast cancer cells transfected to overexpress IGFBP-3, the cell population changed from a state of relative cell-cycle arrest to one of insensitivity to the inhibitory effect of IGFBP-3, in which cell growth was uninhibited. Overexpression of IGFBP-2 and enhanced proliferation in Y-1 adrenocortical tumors via IGF-independent actions also have been described [54] . An alternative explanation is increased induction of the regulators of IGFBP-2 and -3. Fanayan et al. [55] reported that IGFBP-3 inhibitory signaling requires an active TGF␤ signaling pathway. Conceivably, then, abrogation of this pathway may stimulate IGFBP-3 growth signaling effects. Consistent with this view, Kansra et al. [56] has shown that the induction of IGFBP-3 by TGF␤ is associated with enhanced growth in colon cancer.
In summary, the results of the present study demonstrate that cell number is significantly increased in both fetal and maternal tissues of placentomes in NT pregnancies compared with AI/IVP controls. Increased production of IGFBP-2 and -3 in these pregnancies may provide a causal explanation for the increase in cell number and, potentially, increased placental size observed in NT pregnancies. Whether these factors are part of the cause of placental dysfunction or merely a consequence of abnormal placental development is yet to be established.
